Fei Duan
Nanyang Technological University(SG)Guangzhou Education Bureau(CN)Zhong Ke San Huan (China)(CN)China Southern Power Grid (China)(CN)Power Grid Corporation (India)(IN)Northeastern University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis, Adenosine and Purinergic Signaling, Advanced Breast Cancer Therapies, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity(2014)390 cited
- → Neoadjuvant relatlimab and nivolumab in resectable melanoma(2022)317 cited
- → Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma(2020)305 cited
- → Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation(2010)255 cited
- → Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial(2022)244 cited
- → A simple and powerful co-delivery system based on pH-responsive metal-organic frameworks for enhanced cancer immunotherapy(2017)